daclizumab

Type: Product
Name: daclizumab
First reported Apr 17 2014 - Updated Apr 17 2014 - 1 reports

AbbVie Candidate in Pivotal Study - Analyst Blog

Earlier this week, AbbVie Inc. ( ABBV ) provided an update on its experimental cancer drug which has been moved into a pivotal study (n=900). AbbVie's PARP inhibitor, veliparib's safety and efficacy will be evaluated in a randomized, placebo-controlled, ... [Published Nasdaq - Apr 17 2014]
First reported Apr 16 2014 - Updated Apr 16 2014 - 1 reports

Responder definition of the Multiple Sclerosis Impact Scale physical impact subscale for patients with physical worsening

Background: The 29-item Multiple Sclerosis Impact Scale (MSIS-29) was developed to examine the impact of multiple sclerosis (MS) on physical and psychological functioning from a patient’s perspective. Objective: To determine the responder definition (RD) ... [Published Multiple Sclerosis Journal RSS feed -- OnlineFi ... - Apr 16 2014]
First reported Apr 15 2014 - Updated Apr 15 2014 - 1 reports

Biogen Idec to share latest neurology data at AAN 2014

:41 in Pharmaceutical Company Product News Biogen Idec has announced that it will be presenting new data on its current and future neurological disease therapies at the American Academy of Neurology (AAN) annual meeting. The company will attend the conference ... [Published Zenopa - Apr 15 2014]
First reported Apr 14 2014 - Updated Apr 14 2014 - 1 reports

Biogen to Present Clinical Data from Neurology Portfolio at AAN Annual Meeting

- Two-Year Data from Pivotal Phase 3 ADVANCE Study for PLEGRIDY™ (Peginterferon Beta-1a) to Be Presented -- New TECFIDERA® (dimethyl fumarate) Data Underscore Efficacy, Consistent with Growing Global Experience with Greater than 65,000 Patients Treated ... [Published Benzinga.com - Apr 14 2014]
First reported Apr 05 2014 - Updated Apr 05 2014 - 1 reports

Atgam anti cancer drugs anticancer agents suppliers and exporters in delhi

South Delhi Pharma was established in the year 1996 with the Mission: To Deliver the best of services to the Health Care Professionals by catering to the need of their Patients and their Institutions. Our Vision: To be recognized as the Best Service ... [Published FreePressIndex.com - Apr 05 2014]
First reported Apr 01 2014 - Updated Apr 01 2014 - 1 reports

Disease-activity-free status in patients with relapsing-remitting multiple sclerosis treated with daclizumab high-yield process in the SELECT study

Eva Havrdova, Gavin Giovannoni, Dusan Stefoski, Samantha Forster, Kimberly Umans, Lahar Mehta, Steven Greenberg, Jacob ElkinsApr 1, 2014; 20:464-470Research Papers ... [Published Mult Scler: Most-Read Full-Text Articles - Apr 01 2014]
First reported Mar 27 2014 - Updated Mar 27 2014 - 2 reports

Can AbbVie's Legacy Products Deliver Further Growth?

Levothyroxine, the active ingredient in the hypothyroidism drug Synthroid, degrades quickly with exposure to light, moisture, oxygen, and carbohydrate excipients. Consequently, manufacturing complexities combined with a very narrow dosing range makes ... [Published Motley Fool - Mar 27 2014]
First reported Mar 21 2014 - Updated Mar 21 2014 - 1 reports

Daclizumab extension study results: impact on progression confirmed

Another treatment option for RRMS. What about progressive MS? #MSBlog #MSResearch "The daclizumab extension was finally published this week in the Lancet Neurology (abstract below). I first presented the results at the last year's AAN meeting in San ... [Published Multiple Sclerosis Research - Mar 21 2014]
First reported Mar 19 2014 - Updated Mar 19 2014 - 1 reports

[Articles] Daclizumab high-yield process in relapsing-remitting multiple sclerosis (SELECTION): a multicentre, randomised, double-blind extension trial

Adverse events and immunogenicity were not increased in the second year of continuous treatment with daclizumab HYP or during treatment washout and re-initiation. These results support further assessment of daclizumab HYP for relapsing-remitting multiple ... [Published The Lancet Neurology online - Mar 19 2014]
First reported Mar 19 2014 - Updated Mar 19 2014 - 1 reports

[Comment] Daclizumab in multiple sclerosis: a high-yield extension study

Monoclonal antibodies have emerged as effective treatments for patients with multiple sclerosis. They bind to specific proteins on the surface of the immune cells that are involved in the cascade of events leading to pathological changes associated with ... [Published The Lancet Neurology online - Mar 19 2014]
First reported Mar 11 2014 - Updated Mar 11 2014 - 1 reports

Disease-activity-free status in patients with relapsing-remitting multiple sclerosis treated with daclizumab high-yield process in the SELECT study

Background: Daclizumab high-yield process (DAC HYP) is a humanized anti-CD25 monoclonal antibody that inhibits high-affinity interleukin-2 receptor signaling. Objective: The objective of this paper is to assess the proportion of DAC HYP- versus placebo-treated ... [Published Multiple Sclerosis Journal current issue - Mar 11 2014]
First reported Nov 08 2013 - Updated Nov 08 2013 - 2 reports

Daclizumab reduces CD25 levels on T cells through monocyte-mediated trogocytosis

Daclizumab is a humanized monoclonal antibody that prevents interleukin-2 (IL-2) binding to CD25, blocking IL-2 signaling by cells that require high-affinity IL-2 receptors to mediate IL-2 signaling. The phase 2a CHOICE study evaluating daclizumab as ... [Published Multiple Sclerosis Journal RSS feed -- OnlineFi ... - Nov 08 2013]

Quotes

...Dr Alfred Sandrock, group senior vice-president and chief medical officer at Biogen Idec, said: "The breadth of data we are presenting at AAN reinforces our enduring commitment to reducing the impact of multiple sclerosis and other serious neurodegenerative diseases." Earlier this month, the company announced the appointment of Dr Adam Koppel as its new senior vice-president and chief strategy officer, effective as...
Mr. Chaoui added, "We are committed to strengthening our presence in Asia and offering patients and healthcare providers in the Asian region access to new and innovative treatment options. This agreement is also an important step for our specialty focused expansion in China. It will help drive our business growth in key emerging markets, which is one of UCB's top strategic priorities."
...I first presented the results at the last year's AAN meeting in San Diego (slides below). "Why is daclizumab so interesting? It Is one of the drugs that dissociates relapses from disease progression; i e. it appears to have a greater impact on disability progression than you would expect from its impact on relapses. The other drugs that do this are ibudilast and laquinimod. I suspect these agents as a class are having a greater impact on downstream neurodegenerative events than they are having on usptream inflammatory events. Saying this daclizumab does have a reasonable impact on relapse rates with a reduction in the annualised relapse rate of over 50%. Daclizumab also has a"
#MSBlog : to repurpose or not, that is the question? This is a reposting from December 2012. "The length of time it takes to develop new drugs is frustratingly long and expensive. A short-cut is to repurpose existing drugs; i e. drugs that have already been through development and are either licensed for another indication or sitting on the shelf. If you repurpose these drugs for MS, the development time and costs are potentially shortened. The incentive for repurposing drugs is already in place if the Pharma company can get a new patent on the drug."

More Content

All (38) | News (20) | Reports (0) | Blogs (18) | Audio/Video (0) | Fact Sheets (0) | Press Releases (0)
sort by: Date | Relevance
Biogen Idec's CEO Discusses Q1 2014 Earnings Re... [Published Seeking Alpha - Apr 24 2014]
Tissue engineering methods and compositions [Published PharmCast - Apr 22 2014]
Company Update (NASDAQ:BIIB): Biogen Idec Signs... [Published Jutia Group - Apr 21 2014]
AbbVie Candidate in Pivotal Study - Analyst Blog [Published Nasdaq - Apr 17 2014]
AbbVie Candidate in Pivotal Study [Published Zacks.com - Apr 17 2014]
Responder definition of the Multiple Sclerosis ... [Published Multiple Sclerosis Journal RSS feed -- OnlineFi ... - Apr 16 2014]
Biogen Idec to share latest neurology data at A... [Published Zenopa - Apr 15 2014]
Biogen Idec to Present New Clinical Data from I... [Published Investor's Business Daily - Apr 14 2014]
Biogen to Present Clinical Data from Neurology ... [Published Benzinga.com - Apr 14 2014]
Biogen Idec and UCB Enter Agreements to Commerc... [Published FirstWord Pharma - Apr 09 2014]
Atgam anti cancer drugs anticancer agents suppl... [Published FreePressIndex.com - Apr 05 2014]
Stock Update (NASDAQ:BIIB): Biogen Idec to Repo... [Published Jutia Group - Apr 01 2014]
Disease-activity-free status in patients with r... [Published Mult Scler: Most-Read Full-Text Articles - Apr 01 2014]
Company Update: Biogen Idec Inc (NASDAQ:BIIB) –... [Published Jutia Group - Mar 28 2014]
Can AbbVie's Legacy Products Deliver Further Gr... [Published Motley Fool - Mar 27 2014]
Can AbbVie's Legacy Products Deliver Further Gr... [Published Motley Fool Discussion Boards - Mar 27 2014]
Daclizumab extension study results: impact on p... [Published Multiple Sclerosis Research - Mar 21 2014]
Biogen's Winning Strategy [Published Seeking Alpha - Mar 20 2014]
Politics: drug repurposing [Published Multiple Sclerosis Research - Mar 20 2014]
Biogen Faces Delay in FDA Action Date [Published Yahoo! Finance - Mar 19 2014]
[Articles] Daclizumab high-yield process in rel... [Published The Lancet Neurology online - Mar 19 2014]
[Comment] Daclizumab in multiple sclerosis: a h... [Published The Lancet Neurology online - Mar 19 2014]
Disease-activity-free status in patients with r... [Published Multiple Sclerosis Journal current issue - Mar 11 2014]
Daclizumab reduces CD25 levels on T cells throu... [Published Multiple Sclerosis Journal current issue - Feb 03 2014]
Daclizumab reduces CD25 levels on T cells throu... [Published Mult Scler: Most-Read Full-Text Articles - Feb 01 2014]
Deals Of The Week Looks at The Intersection Of ... [Published The IN VIVO Blog - Jan 31 2014]
UCB Pharma to commercialize Biogen's Idec produ... [Published Pharmaceutical Business Review - Jan 31 2014]
publications 2013 [Published Multiple Sclerosis Research - Jan 07 2014]
Why the results of laquinimod are so important? [Published Multiple Sclerosis Research - Jan 07 2014]
Daclizumab is effective in people with high dis... [Published Multiple Sclerosis Research - Jan 06 2014]
1 2
In Focus
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
Content Volume
Document Volume
Network
Network

Blogs

sort by: Date | Relevance
Responder definition of the Multiple Sclerosis ... [Published Multiple Sclerosis Journal RSS feed -- OnlineFi ... - Apr 16 2014]
Background: The 29-item Multiple Sclerosis Impact Scale (MSIS-29) was developed to examine the impact of multiple sclerosis (MS) on physical and psychological functioning from a patient’s perspective. Objective: To determine the responder definition (RD) ...
Disease-activity-free status in patients with r... [Published Mult Scler: Most-Read Full-Text Articles - Apr 01 2014]
Eva Havrdova, Gavin Giovannoni, Dusan Stefoski, Samantha Forster, Kimberly Umans, Lahar Mehta, Steven Greenberg, Jacob ElkinsApr 1, 2014; 20:464-470Research Papers ...
Daclizumab extension study results: impact on p... [Published Multiple Sclerosis Research - Mar 21 2014]
Another treatment option for RRMS. What about progressive MS? #MSBlog #MSResearch "The daclizumab extension was finally published this week in the Lancet Neurology (abstract below). I first presented the results at the last year's AAN meeting in San ...
Politics: drug repurposing [Published Multiple Sclerosis Research - Mar 20 2014]
#MSBlog : to repurpose or not, that is the question? This is a reposting from December 2012. "The length of time it takes to develop new drugs is frustratingly long and expensive. A short-cut is to repurpose existing drugs; i.e. drugs that have already ...
[Articles] Daclizumab high-yield process in rel... [Published The Lancet Neurology online - Mar 19 2014]
Adverse events and immunogenicity were not increased in the second year of continuous treatment with daclizumab HYP or during treatment washout and re-initiation. These results support further assessment of daclizumab HYP for relapsing-remitting multiple ...
1 2 3 4
Contact Us
Sales
Support


Freebase CC-BY Some image thumbnails are sourced from Freebase, licensed under CC-BY

Copyright (C) 2014 Silobreaker Ltd. All rights reserved.
The selection and placement of stories and images on any Silobreaker page are determined automatically by a computer program.
The time or date displayed reflects when an article was added to or updated in Silobreaker.